Search research articles
Contact Us
Filters
Showing results (491-500 of 522) with videos related to
Page
of 53
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 16, 2000
Predictive role of interphase cytogenetics for survival of patients with multiple myeloma
R Königsberg, N Zojer, J Ackermann, et al.
Journal of Diabetes Research
|
November 4, 2016
Qualitative Parameters of the Colonic Flora in Patients with HNF1A-MODY Are Different from Those Observed in Type 2 Diabetes Mellitus
Sandra Mrozinska, Piotr Radkowski, Tomasz Gosiewski, et al.
Leukemia
|
April 26, 2017
Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes
P Hari, M-V Mateos, R Abonour, et al.
Journal of Lipid Research
|
January 18, 2005
High-level lipoprotein [a] expression in transgenic mice: evidence for oxidized phospholipids in lipoprotein [a] but not in low density lipoproteins
Matthias Schneider, Joseph L Witztum, Stephen G Young, et al.
Thrombosis Research
|
September 10, 2014
Lupus anticoagulant and thrombosis in splenic marginal zone lymphoma
J Gebhart, K Lechner, C Skrabs, et al.
Molecular Medicine (Cambridge, Mass.)
|
September 14, 2022
Variants influencing age at diagnosis of HNF1A-MODY
Agnieszka H Ludwig-Słomczyńska, Michał T Seweryn, Piotr Radkowski, et al.
Leukemia & Lymphoma
|
March 26, 2002
Dose escalation of ara-c may improve response rates in a subgroup of chronic myeloid leukemia patients with poor response to interferon-alpha and low-dose ara-C
W Hilbe, T Kühr, U Apfelbeck, et al.
Journal of Hematology & Oncology
|
January 18, 2018
Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel
J Caers, B Paiva, E Zamagni, et al.
Leukemia
|
February 5, 2011
Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement
M A Dimopoulos, A Palumbo, M Attal, et al.
Leukemia
|
February 6, 2014
Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma
M A Dimopoulos, X Leleu, A Palumbo, et al.
Page
of 53
Search research articles
Search
Showing results (491-500 of 522) with videos related to
Sort By:
Page
of 53
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 16, 2000
Predictive role of interphase cytogenetics for survival of patients with multiple myeloma
R Königsberg, N Zojer, J Ackermann, et al.
Journal of Diabetes Research
|
November 4, 2016
Qualitative Parameters of the Colonic Flora in Patients with HNF1A-MODY Are Different from Those Observed in Type 2 Diabetes Mellitus
Sandra Mrozinska, Piotr Radkowski, Tomasz Gosiewski, et al.
Leukemia
|
April 26, 2017
Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes
P Hari, M-V Mateos, R Abonour, et al.
Journal of Lipid Research
|
January 18, 2005
High-level lipoprotein [a] expression in transgenic mice: evidence for oxidized phospholipids in lipoprotein [a] but not in low density lipoproteins
Matthias Schneider, Joseph L Witztum, Stephen G Young, et al.
Thrombosis Research
|
September 10, 2014
Lupus anticoagulant and thrombosis in splenic marginal zone lymphoma
J Gebhart, K Lechner, C Skrabs, et al.
Molecular Medicine (Cambridge, Mass.)
|
September 14, 2022
Variants influencing age at diagnosis of HNF1A-MODY
Agnieszka H Ludwig-Słomczyńska, Michał T Seweryn, Piotr Radkowski, et al.
Leukemia & Lymphoma
|
March 26, 2002
Dose escalation of ara-c may improve response rates in a subgroup of chronic myeloid leukemia patients with poor response to interferon-alpha and low-dose ara-C
W Hilbe, T Kühr, U Apfelbeck, et al.
Journal of Hematology & Oncology
|
January 18, 2018
Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel
J Caers, B Paiva, E Zamagni, et al.
Leukemia
|
February 5, 2011
Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement
M A Dimopoulos, A Palumbo, M Attal, et al.
Leukemia
|
February 6, 2014
Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma
M A Dimopoulos, X Leleu, A Palumbo, et al.
Page
of 53